



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents  
Washington, D.C. 20231

1600

0800 Box Seq 8 VNK  
PATENT  
Attorney Docket No.: 015280-317100US  
DHHS Ref. No.: E-059-97/1  
1646

On May 11, 2000

TOWNSEND and TOWNSEND and CREW LLP

By: [Signature]

#  
dB  
KO  
H1-10

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

FitzGerald *et al.*

Application No.: 09/381,497

Filed: September 20, 1999

For: RECOMBINANT ANTIBODIES  
AND IMMUNOCONJUGATES  
TARGETED TO CD-22 BEARING  
CELLS AND TUMORS

Examiner: Not yet assigned

Art Unit: Not yet assigned

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

PRELIMINARY AMENDMENT

Box SEQUENCE  
Assistant Commissioner for Patents  
Washington, D.C. 20231

RECEIVED

RECEIVED

JUN 05 2000

MAY 25 2000

TECH CENTER 1600/2900

TECH CENTER 1600/2900

Sir:

In order to comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, Applicants submit herewith the required paper copy and computer readable copy of the Sequence Listing. Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

IN THE SPECIFICATION:

On page 4, line 10, insert (SEQ ID NO:4; nucleotides = SEQ ID NO:3) after  
B<sup>1</sup> "RFB4 light".

On page 4, line 10, insert (SEQ ID NO:2; nucleotides = SEQ ID NO:1) after  
B<sup>2</sup> "and heavy".